STOCK TITAN

Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 10:35 a.m. Eastern Time in New York. CEO Kevin Gorman and CFO Matt Abernethy will lead the presentation. The event will be webcast live, accessible via the company's website, with a replay available one hour post-event and archived for a month. Neurocrine is committed to developing treatments for complex neurological, neuroendocrine, and neuropsychiatric disorders, boasting several FDA-approved therapies.

Positive
  • None.
Negative
  • None.

SAN DIEGO, Sept. 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 20th Annual Global Healthcare Conference at 10:35 a.m. Eastern Time on Tuesday, September 13, 2022 in New York. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, as well as over a dozen mid-to-late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, Twitter, and Facebook. (*in collaboration with AbbVie)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-conference-301618397.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences present at the Morgan Stanley Global Healthcare Conference?

Neurocrine Biosciences will present on September 13, 2022, at 10:35 a.m. Eastern Time.

Who will represent Neurocrine Biosciences at the conference?

CEO Kevin Gorman and CFO Matt Abernethy will represent Neurocrine Biosciences.

How can I access the Neurocrine Biosciences presentation?

The presentation can be accessed live on Neurocrine's website under the Investors section.

Will there be a replay of the Neurocrine Biosciences presentation available?

Yes, a replay will be available approximately one hour after the conclusion of the event.

What is the focus of Neurocrine Biosciences?

Neurocrine Biosciences focuses on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders.

Neurocrine Biosciences Inc

NASDAQ:NBIX

NBIX Rankings

NBIX Latest News

NBIX Stock Data

11.88B
100.64M
0.99%
96.04%
2.59%
Drug Manufacturers - Specialty & Generic
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO